ARCA Biopharma announces 1-for-12 reverse stock split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2024
0mins
Should l Buy ?
Reverse Stock Split Announcement: ARCA Biopharma's board has approved a 1-for-12 reverse stock split of its common stock, which will take effect on September 3 following the merger with Oruka Therapeutics.
Stockholder Approval: The reverse stock split was sanctioned by ARCA's stockholders during a special meeting on August 22, allowing the board to implement a split ratio between 1-for-6 and 1-for-12.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
